Contrasting IM Cannabis (IMCC) and Its Rivals

IM Cannabis (NASDAQ:IMCC – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare IM Cannabis to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, valuation and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for IM Cannabis and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IM Cannabis 1 0 0 0 1.00
IM Cannabis Competitors 7845 13797 25807 1039 2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.14%. Given IM Cannabis’ competitors stronger consensus rating and higher probable upside, analysts plainly believe IM Cannabis has less favorable growth aspects than its competitors.

Volatility and Risk

IM Cannabis has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500. Comparatively, IM Cannabis’ competitors have a beta of -0.04, meaning that their average stock price is 104% less volatile than the S&P 500.

Profitability

This table compares IM Cannabis and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IM Cannabis -68.64% N/A -93.43%
IM Cannabis Competitors -2,398.26% -203.62% -15.08%

Insider & Institutional Ownership

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares IM Cannabis and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
IM Cannabis $39.17 million -$8.10 million -0.01
IM Cannabis Competitors $18.33 billion $3.19 billion 562.78

IM Cannabis’ competitors have higher revenue and earnings than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

IM Cannabis competitors beat IM Cannabis on 10 of the 13 factors compared.

About IM Cannabis

(Get Free Report)

IM Cannabis Corp. (NASDAQ: IMCC) is a medical cannabis company focused primarily on the Israeli and German markets. The company develops, sources, imports, distributes and markets medical cannabis products under the IMC brand, serving patients through pharmacies, clinics and other authorized channels. In Israel, IM Cannabis is involved in the supply of medical cannabis products, including flower and other cannabis-based offerings, through affiliated cultivation, processing and distribution operations.

Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.